ATE337004T1 - Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz - Google Patents
Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienzInfo
- Publication number
- ATE337004T1 ATE337004T1 AT02735506T AT02735506T ATE337004T1 AT E337004 T1 ATE337004 T1 AT E337004T1 AT 02735506 T AT02735506 T AT 02735506T AT 02735506 T AT02735506 T AT 02735506T AT E337004 T1 ATE337004 T1 AT E337004T1
- Authority
- AT
- Austria
- Prior art keywords
- mangafodipir
- treat hepatocellular
- hepatocellular insufficiency
- insufficiency
- treat
- Prior art date
Links
- QDQFSBKXQQZVTB-UHFFFAOYSA-L 2-[2-[carboxylatomethyl-[[2-methyl-3-oxido-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[2-methyl-3-oxido-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]acetate;hydron;manganese(2+) Chemical compound [H+].[H+].[H+].[H+].[H+].[H+].[Mn+2].CC1=NC=C(COP([O-])([O-])=O)C(CN(CCN(CC([O-])=O)CC=2C(=C(C)N=CC=2COP([O-])([O-])=O)[O-])CC([O-])=O)=C1[O-] QDQFSBKXQQZVTB-UHFFFAOYSA-L 0.000 title abstract 2
- 229960002382 mangafodipir Drugs 0.000 title abstract 2
- 238000009109 curative therapy Methods 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0105606A FR2823977B1 (fr) | 2001-04-26 | 2001-04-26 | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE337004T1 true ATE337004T1 (de) | 2006-09-15 |
Family
ID=8862711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02735506T ATE337004T1 (de) | 2001-04-26 | 2002-04-26 | Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7351722B2 (de) |
| EP (1) | EP1381364B1 (de) |
| JP (1) | JP4371197B2 (de) |
| AT (1) | ATE337004T1 (de) |
| CA (1) | CA2443838A1 (de) |
| DE (1) | DE60214152T2 (de) |
| ES (1) | ES2271265T3 (de) |
| FR (1) | FR2823977B1 (de) |
| PT (1) | PT1381364E (de) |
| WO (1) | WO2002087579A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| WO2009078794A1 (en) | 2007-12-14 | 2009-06-25 | Pledpharma Ab | Compounds for use in the treatment of cancer |
| EP2451457B1 (de) | 2009-07-06 | 2018-03-07 | Pledpharma AB | Pharmazeutische zusammensetzungen und therapeutische verfahren mit einer kombination aus einer mangankomplexverbindung und einer manganfreien komplexform der verbindung |
| CA2862736C (en) | 2012-01-05 | 2020-09-08 | Pledpharma Ab | Mixed metal complexes and methods |
| CA3010915C (en) * | 2016-01-11 | 2024-06-04 | Pledpharma Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| CN110139673B (zh) | 2016-11-14 | 2022-03-22 | 卡尔森图纳投资公司 | 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613182D0 (en) * | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
-
2001
- 2001-04-26 FR FR0105606A patent/FR2823977B1/fr not_active Expired - Fee Related
-
2002
- 2002-04-26 PT PT02735506T patent/PT1381364E/pt unknown
- 2002-04-26 ES ES02735506T patent/ES2271265T3/es not_active Expired - Lifetime
- 2002-04-26 JP JP2002584924A patent/JP4371197B2/ja not_active Expired - Fee Related
- 2002-04-26 AT AT02735506T patent/ATE337004T1/de not_active IP Right Cessation
- 2002-04-26 WO PCT/FR2002/001457 patent/WO2002087579A1/fr not_active Ceased
- 2002-04-26 DE DE60214152T patent/DE60214152T2/de not_active Expired - Lifetime
- 2002-04-26 CA CA002443838A patent/CA2443838A1/fr not_active Abandoned
- 2002-04-26 EP EP02735506A patent/EP1381364B1/de not_active Expired - Lifetime
- 2002-04-26 US US10/475,555 patent/US7351722B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7351722B2 (en) | 2008-04-01 |
| EP1381364B1 (de) | 2006-08-23 |
| ES2271265T3 (es) | 2007-04-16 |
| DE60214152T2 (de) | 2007-07-19 |
| PT1381364E (pt) | 2007-01-31 |
| DE60214152D1 (de) | 2006-10-05 |
| JP4371197B2 (ja) | 2009-11-25 |
| WO2002087579A1 (fr) | 2002-11-07 |
| JP2004526792A (ja) | 2004-09-02 |
| CA2443838A1 (fr) | 2002-11-07 |
| FR2823977B1 (fr) | 2006-12-01 |
| US20040142907A1 (en) | 2004-07-22 |
| EP1381364A1 (de) | 2004-01-21 |
| FR2823977A1 (fr) | 2002-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE50212701D1 (de) | Bestrahlungsanordnung zur behandlung von akne und aknenarben | |
| ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| ATE414512T1 (de) | Kombinationstherapie zur behandlung von krebs | |
| ATE366569T1 (de) | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| NO20025405D0 (no) | Modulatorer for TNF-alfa-signalisering | |
| DE60218153D1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
| ATE337004T1 (de) | Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE380554T1 (de) | Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie | |
| ATE264101T1 (de) | Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose | |
| DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
| DE60217653D1 (de) | Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
| ATE291921T1 (de) | Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| ATE303151T1 (de) | Verwendung von mntbap zur behandlung von hepatischer insuffizienz | |
| ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
| DE69904297D1 (de) | Neue verwendung von ropivacain zur schmerzbehandlung | |
| DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten | |
| DE10193322D2 (de) | Verwendung von Protonenpumpen-Hemmern zur Behandlung von Erkrankungen des Bewegungsapparates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1381364 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |